PROCEPT BioRobotics | 10-K/A: Annual report (Amendment)
Truist Financial Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating, Cuts Target Price to $70
PROCEPT BioRobotics Analyst Ratings
Truist Cuts Price Target on PROCEPT BioRobotics to $70 From $90, Keeps Buy Rating
PROCEPT BioRobotics Announces Investor Event at 2025 AUA Annual Meeting at the Aria Resort in Las Vegas
BTIG Maintains PROCEPT BioRobotics(PRCT.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: KalVista Pharmaceuticals (KALV), Humana (HUM) and PROCEPT BioRobotics (PRCT)
PROCEPT BioRobotics (PRCT): One of the Best Robotics Stocks to Buy According to Billionaires
Following the chips and AI, the USA may consider launching a national strategy for Siasun Robot&Automation.
① USA companies urge the government to launch a Siasun Robot&Automation national strategy to promote the development of the smart robot Industry and drive the development of next-generation robots in Global competition; ② The USA Association for Advanced Automation recommends that the government adopt tax incentive measures, provide federal funding, and establish a new federal robotics office to expand production capacity and promote the application of AI.
PROCEPT BioRobotics Presented Results From WATER III At European Association of Urology 2025 Annual Congress in Madrid, Spain
WATER III Randomized-Controlled Trial Results Announced at European Association of Urology Comparing Aquablation Therapy to Laser Enucleation
Healthcare Up as Traders Rotate to Less Inflation-Sensitive Sectors -- Health Care Roundup
This Insider Has Just Sold Shares In PROCEPT BioRobotics
PROCEPT BioRobotics Announces Investor Event at 2025 AUA Annual Meeting in Las Vegas, Nevada
William Blair Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating
Buy Rating on PROCEPT BioRobotics: Attractive Entry Point Amidst Growth Potential and Upcoming Clinical Catalysts
Procept Biorobotics Insider Sold Shares Worth $975,810, According to a Recent SEC Filing
Jefferies Maintains PROCEPT BioRobotics(PRCT.US) With Hold Rating, Maintains Target Price $77
Stocks That Could Be Safe From Tariffs Risk Compared to Their Industry Peers
Morgan Stanley Fund: Humanoid robots will gradually enter the mass production phase by 2025.
Currently, the humanoid robot industry both domestically and internationally is mainly divided into three major forces: automotive companies, robot companies, and Internet companies. The primary demand for humanoid robots such as those from Tesla is the ability for scaled production and cost reduction.